Active substances
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RASILEZ HCT 150/25MG FILM COATED TABLET | 150, 25 mg | Film-coated tablet · Oral use | 28 Blister | SAR 101.30 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| RASILEZ HCT 300/12.5MG FILM COATED TABLET | 300, 12.5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 124.40 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| RASILEZ HCT 300/25MG FILM COATED TABLET | 300, 25 mg | Film-coated tablet · Oral use | 28 Blister | SAR 124.40 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TEKTURNA HCT | EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | NODEN PHARMA | Discontinued | 18 Jan 2008 |
Treatment of essential hypertension in adults. Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Treatment of essential hypertension in adults. Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Treatment of essential hypertension in adults. Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.